Hypomethylating agents for urologic cancers

Future Oncology

Volumn 7, Issue 3, 2011, Pages 447-463

  Alva, Ajjai S ^a   Hahn, Noah M ^b   Aparicio, Ana M ^c   Singal, Rakesh ^d   Yellapragada, Sarvari ^a   Sonpavde, Guru ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

hypomethylating agents; prostate cancer; renal cell carcinoma; urologic cancer

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BEVACIZUMAB; BEXAROTENE; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOCETAXEL; ENTINOSTAT; FLUOROURACIL; GEMCITABINE; GIVINOSTAT; MOCETINOSTAT; PACLITAXEL; PANOBINOSTAT; PCI 24781; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; ROMIDEPSIN; TACEDINALINE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DNA METHYLATION; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GERIATRICS; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPOMETHYLATION; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SOLID TUMOR; TESTIS CANCER; THYROID CANCER; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; UROGENITAL TRACT CANCER; UROTHELIUM; UROTHELIUM CANCER; UTERINE CERVIX CANCER; VOMITING;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; HUMANS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 79953138219     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.9     Document Type: Review

References (150)

1. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26(22), 3743-3748 (2008).
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004). (Pubitemid 39315318)
3. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK: Cabazitaxel. Nat. Rev. Drug Discov. 9(9), 677-678 (2010).
4. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
6. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756-1764 (1996). (Pubitemid 26185452)
7. Schmoll HJ, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), V147-V154 (2010).
8. Schmoll HJ, Jordan K, Huddart R, et al. Testicular seminoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), V140-V146 (2010).
9. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N. Engl. J. Med. 357(4), 340-348 (2007). (Pubitemid 47124134)
10. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing mvac and cisca chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8(6), 1050-1055 (1990). (Pubitemid 20200193)
11. Von Der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23(21), 4602-4608 (2005). (Pubitemid 46224062)
12. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27(27), 4454-4461 (2009).
13. Kelly TK, De Carvalho DD, Jones PA: Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28(10), 1069-1078 (2010).
14. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 106(8), 1794-1803 (2006).
15. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 28(4), 562-569 (2010).
16. Silverman LR, Mckenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J. Clin. Oncol. 24(24), 3895-3903 (2006). (Pubitemid 46630737)
17. Christman JK: 5-azacytidine and 5-aza-2′- deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21(35), 5483-5495 (2002). (Pubitemid 34983483)
18. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003). (Pubitemid 37448928)
19. Kawakami T, Okamoto K, Ogawa O, Okada Y: Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. Urology 61(1), 226-230 (2003). (Pubitemid 36151757)
20. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001). (Pubitemid 32165345)
21. Saxonov S, Berg P, Brutlag DL: A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl Acad. Sci. USA 103(5), 1412-1417 (2006). (Pubitemid 43191179)
22. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39(4), 457-466 (2007). (Pubitemid 46514772)
23. Esteller M: Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
24. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196 (1998). (Pubitemid 27435555)
25. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat. Genet. 21(2), 163-167 (1999). (Pubitemid 29070360)
26. Brothman AR, Swanson G, Maxwell TM, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet. Cytogenet. 156(1), 31-36 (2005). (Pubitemid 39601056)
27. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409(6817), 207-211 (2001). (Pubitemid 32144287)
28. Ghoshal K, Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc.) 43(6), 395-422 (2007). (Pubitemid 47234771)
29. Ramachandran K, Gopisetty G, Gordian E, et al. Methylation-mediated repression of GADD45a in prostate cancer and its role as a potential therapeutic target. Cancer Res. 69(4), 1527-1535 (2009).
30. Szyf M, Detich N: Regulation of the DNA methylation machinery and its role in cellular transformation. Prog. Nucleic Acid Res. Mol. Biol. 69, 47-79 (2001). (Pubitemid 33805839)
31. Sorm F, Piskala A, Cihak A, Vesely J: 5-azacytidine, a new, highly effective cancerostatic. Experientia 20(4), 202-203 (1964).
32. Flatau E, Gonzales FA, Michalowsky LA, Jones PA: DNA methylation in 5-aza-2′- deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. Mol. Cell Biol. 4(10), 2098-2102 (1984). (Pubitemid 15209982)
33. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21(1), 103-107 (1999). (Pubitemid 29036293)
34. Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA: Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum. Mol. Genet. 8(12), 2317-2323 (1999). (Pubitemid 29525348)
35. Li LH, Olin EJ, Buskirk HH, Reineke LM: Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 30(11), 2760-2769 (1970).
36. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5(2), E9001 (2010).
37. Qin T, Jelinek J, Si J, Shu J, Issa JP: Mechanisms of resistance to 5-aza-2′- deoxycytidine in human cancer cell lines. Blood 113(3), 659-667 (2009).
38. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23(6), 1019-1028 (2009).
39. Saunthararajah Y, Lavelle D, Desimone J: DNA hypo-methylating agents and sickle cell disease. Br. J. Haematol. 126(5), 629-636 (2004). (Pubitemid 39221297)
40. Weiss AJ, Stambaugh JE, Mastrangelo MJ, Laucius JF, Bellet RE: Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother. Rep. 56(3), 413-419 (1972).
41. Aparicio A, Weber JS: Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr. Opin. Investig. Drugs 3(4), 627-633 (2002).
42. Bellet RE, Mastrangelo MJ, Engstrom PF, Strawitz JG, Weiss AJ, Yarbro JW: Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816). Cancer Chemother. Rep. 58(2), 217-222 (1974).
43. Van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM: Phase I and pharmacokinetic study of 5-aza-2′- deoxycytidine (NSC-127716) in cancer patients. Cancer Res. 46(9), 4831-4836 (1986). (Pubitemid 16000370)
44. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2′- deoxycytidine. Cancer Chemother. Pharmacol. 51(3), 231-239 (2003). (Pubitemid 36469953)
45. Abele R, Clavel M, Dodion P, et al. The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC-127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol. 23(12), 1921-1924 (1987). (Pubitemid 18013335)
46. Clavel M, Monfardini S, Fossa S, Smyth J, Renard J, Kaye SB: 5-aza-2′-deoxycytidine (NSC-127716) in non-seminomatous testicular cancer. Phase II from the EORTC early clinical trials cooperative group and genito-urinary group. Ann. Oncol. 3(5), 399-400 (1992).
47. Thibault A, Figg WD, Bergan RC, et al. A Phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84(1), 87-89 (1998). (Pubitemid 28221854)
48. Schwartsmann G, Schunemann H, Gorini CN, et al. A Phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early Phase II evaluation in patients with inoperable non-small cell lung cancer. Invest. New Drugs 18(1), 83-91 (2000). (Pubitemid 30175899)
49. Jarrard DF, Kinoshita H, Shi Y, et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 58(23), 5310-5314 (1998). (Pubitemid 28551106)
50. Wang LG, Ossowski L, Ferrari AC: Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23(30), 5175-5184 (2004). (Pubitemid 38980350)
51. Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 11(23), 8321-8325 (2005). (Pubitemid 41746943)
52. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res. 11(11), 4097-4106 (2005). (Pubitemid 40791574)
53. Richiardi L, Fiano V, Vizzini L, et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J. Clin. Oncol. 27(19), 3161-3168 (2009).
54. Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE, Day ML: 5-aza-2′- deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin. Cancer Res. 13(7), 2136-2143 (2007). (Pubitemid 46649883)
55. Gravina GL, Marampon F, Di Staso M, et al. 5-azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 70(11), 1166-1178 (2010).
56. Gravina GL, Festuccia C, Millimaggi D, et al. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate 68(7), 793-801 (2008). (Pubitemid 351632951)
57. Pulukuri SM, Rao JS: Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′- deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int. J. Oncol. 26(4), 863-871 (2005).
58. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC: DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor b and induce apoptosis in prostate cancer cell-lines. Prostate 68(2), 210-222 (2008). (Pubitemid 351186233)
59. Pruitt K, Ulku AS, Frantz K, et al. Ras mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J. Biol. Chem. 280(24), 23363-23370 (2005). (Pubitemid 40853250)
60. Ropke A, Buhtz P, Bohm M, et al. Promoter CpG hypermethylation and downregulation of DICE1 expression in prostate cancer. Oncogene 24(44), 6667-6675 (2005). (Pubitemid 41486797)
61. Pang ST, Weng WH, Flores-Morales A, et al. Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. Prostate 66(2), 157-172 (2006). (Pubitemid 43191237)
62. Zaman MS, Chen Y, Deng G, et al. The functional significance of microRNA-145 in prostate cancer. Br. J. Cancer 103(2), 256-264 (2010).
63. Chen MF, Chen WC, Chang YJ, Wu CF, Wu CT: Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. J. Mol. Med. 88(9), 953-962 (2010).
64. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM: Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol. Cancer Res. 7(4), 523-535 (2009).
65. Izbicka E, Macdonald JR, Davidson K, Lawrence RA, Gomez L, Von Hoff DD: 5,6 dihydro-5′-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells. Anticancer Res. 19(2A), 1285-1291 (1999). (Pubitemid 29257572)
66. Kitagawa Y, Kyo S, Takakura M, et al. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of HTERT. Clin. Cancer Res. 6(7), 2868-2875 (2000). (Pubitemid 30482129)
67. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142(11), 4795-4805 (2001). (Pubitemid 33022355)
68. Wang Y, Kreisberg JI, Ghosh PM: Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/AKT pathway in prostate cancer. Curr. Cancer Drug Targets 7(6), 591-604 (2007). (Pubitemid 47358145)
69. Gravina GL, Biordi L, Martella F, et al. Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int. J. Oncol. 35(5), 1133-1139 (2009).
70. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV: Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol. Cancer Ther. 9(1), 33-45 (2010).
71. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64(6), 1975-1986 (2004). (Pubitemid 38339443)
72. Festuccia C, Gravina GL, D'Alessandro AM, et al. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr. Relat. Cancer 16(2), 401-413 (2009).
73. Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis M: Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4- hydroperoxycyclophosphamide with human tumor cells. Cancer Res. 50(15), 4572-4577 (1990). (Pubitemid 20230394)
74. Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt H: Recruitment of DNA methyltransferase I to DNA repair sites. Proc. Natl Acad. Sci. USA 102(25), 8905-8909 (2005). (Pubitemid 40881051)
75. Lin X, Asgari K, Putzi MJ, et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61(24), 8611-8616 (2001). (Pubitemid 34013864)
76. Singal R, Van Wert J, Bashambu M: Cytosine methylation represses glutathione S-transferase p1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res. 61(12), 4820-4826 (2001). (Pubitemid 32691897)
77. Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71(1), 161-167 (2008). (Pubitemid 351173282)
78. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG: GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell Biochem. 91(3), 540-552 (2004).
79. Roupret M, Hupertan V, Catto JW, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer 122(4), 952-956 (2008).
80. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91(21), 9700-9704 (1994). (Pubitemid 24311875)
81. Morris MR, Hesson LB, Wagner KJ, et al. Multigene methylation analysis of Wilms? tumour and adult renal cell carcinoma. Oncogene 22(43), 6794-6801 (2003). (Pubitemid 37372219)
82. Onay H, Pehlivan S, Koyuncuoglu M, Kirkali Z, Ozkinay F: Multigene methylation analysis of conventional renal cell carcinoma. Urol. Int. 83(1), 107-112 (2009).
83. Nojima D, Nakajima K, Li LC, et al. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol. Carcinog. 32(1), 19-27 (2001).
84. Morris MR, Maher ER: Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med. 2(9), 59 (2010).
85. Morris MR, Gentle D, Abdulrahman M, et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 65(11), 4598-4606 (2005). (Pubitemid 40740795)
86. Kawai Y, Sakano S, Suehiro Y, et al. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann. Oncol. 21(8), 1612-1617 (2010).
87. Arai E, Ushijima S, Tsuda H, et al. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin. Cancer Res. 14(17), 5531-5539 (2008).
88. Christoph F, Kempkensteffen C, Weikert S, et al. Methylation of tumour suppressor genes apaf-1 and dapk-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br. J. Cancer 95(12), 1701-1707 (2006). (Pubitemid 44950797)
89. Reu FJ, Bae SI, Cherkassky L, et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J. Clin. Oncol. 24(23), 3771-3779 (2006). (Pubitemid 46622316)
90. Mcronald FE, Morris MR, Gentle D, et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol. Cancer 8, 31 (2009).
91. Morrissey C, Martinez A, Zatyka M, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 61(19), 7277-7281 (2001). (Pubitemid 32946526)
92. Gonzalgo ML, Yegnasubramanian S, Yan G, et al. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin. Cancer Res. 10(21), 7276-7283 (2004). (Pubitemid 39487715)
93. Wilhelm CS, Kelsey KT, Butler R, et al. Implications of LINE1 methylation for bladder cancer risk in women. Clin. Cancer Res. 16(5), 1682-1689 (2010).
94. Costa VL, Henrique R, Danielsen SA, et al. Three epigenetic biomarkers, GDF15, TMEFF2 and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res. 16(23), 5842-5851 (2010).
95. Aleman A, Adrien L, Lopez-Serra L, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br. J. Cancer 98(2), 466-473 (2008). (Pubitemid 351161244)
96. Kawakami T, Shiina H, Igawa M, et al. Inactivation of the hMSH3 mismatch repair gene in bladder cancer. Biochem. Biophys. Res. Commun. 325(3), 934-942 (2004). (Pubitemid 39487962)
97. Urakami S, Shiina H, Enokida H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/b catenin signaling pathway. Clin. Cancer Res. 12(2), 383-391 (2006). (Pubitemid 43166125)
98. Kim WJ, Kim EJ, Jeong P, et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 65(20), 9347-9354 (2005). (Pubitemid 41508002)
99. Aleman A, Cebrian V, Alvarez M, et al. Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res. 14(24), 8236-8243 (2008).
100. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 13(7), 2046-2053 (2007). (Pubitemid 46649871)
101. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and blad-er cancer detection. J. Natl Cancer Inst. 98(14), 996-1004 (2006). (Pubitemid 44288164)
102. Marsit CJ, Houseman EA, Christensen BC, et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS One 5(8), E12334 (2010).
103. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 23(13), 2903-2910 (2005). (Pubitemid 46224108)
104. Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell Biol. 24(3), 1270-1278 (2004). (Pubitemid 38112188)
105. Liu X, Dai X, Wu B: Study of 5-aza-CdR on transcription regulation of RASSF1A gene in the BIU87 cell line. Urol. Int. 82(1), 108-112 (2009).
106. Bender CM, Pao MM, Jones PA: Inhibition of DNA methylation by 5-aza-2′- deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58(1), 95-101 (1998). (Pubitemid 28027723)
107. Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67(13), 6400-6408 (2007). (Pubitemid 47037524)
108. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 62(22), 6456-6461 (2002). (Pubitemid 35364106)
109. Karam JA, Fan J, Stanfield J, et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int. J. Cancer 120(8), 1795-1802 (2007). (Pubitemid 46399368)
110. Beyrouthy MJ, Garner KM, Hever MP, et al. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res. 69(24), 9360-9366 (2009).
111. Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM, Chan WY: Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br. J. Cancer 102(2), 419-427 (2010).
112. Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER, Latif F: Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 22(3), 461-466 (2003). (Pubitemid 36194343)
113. Omisanjo OA, Biermann K, Hartmann S, et al. DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. Histochem. Cell Biol. 127(2), 175-181 (2007). (Pubitemid 46147271)
114. Wermann H, Stoop H, Gillis AJ, et al. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J. Pathol. 221(4), 433-442 (2010).
115. Sonpavde G, Aparicio AM, Zhan F, et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol. Oncol. DOI:10.1016/j.urolonc.2009.09.015 (2009) (Epub ahead of print).
116. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R: Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin. Chem. 52(10), 1833-1842 (2006). (Pubitemid 44470688)
117. Florl AR, Steinhoff C, Muller M, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 91(5), 985-994 (2004). (Pubitemid 39273795)
118. Roth BJ, Elson P, Sledge GW Jr, Einhorn LH, Trump DL: 5-azacytidine (NSC 102816) in refractory germ cell tumors. A Phase II trial of the eastern cooperative oncology group. Invest. New Drugs 11(2-3), 201-202 (1993).
119. Frommer M, Mcdonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89(5), 1827-1831 (1992).
120. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28(8), E32 (2000).
121. Aparicio A, North B, Barske L, et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3), 176-184 (2009).
122. Karimi M, Johansson S, Stach D, et al. LUMA (luminometric methylation assay) - a high throughput method to the analysis of genomic DNA methylation. Exp. Cell Res. 312(11), 1989-1995 (2006). (Pubitemid 43850924)
123. Oakeley EJ: DNA methylation analysis: a review of current methodologies. Pharmacol. Ther. 84(3), 389-400 (1999).
124. Wagner I, Capesius I: Determination of 5-methylcytosine from plant DNA by high-performance liquid chromatography. Biochim. Biophys. Acta 654(1), 52-56 (1981). (Pubitemid 11055180)
125. Yoo CB, Cheng JC, Jones PA: Zebularine: a new drug for epigenetic therapy. Biochem. Soc. Trans. 32(Pt 6), 910-912 (2004). (Pubitemid 39655501)
126. Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi JJ Jr: Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J. Med. Chem. 34(11), 3280-3284 (1991).
127. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP: Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol. 321(4), 591-599 (2002). (Pubitemid 36124798)
128. Suzuki M, Shinohara F, Nishimura K, Echigo S, Rikiishi H: Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int. J. Oncol. 31(6), 1449-1456 (2007).
129. Billam M, Sobolewski MD, Davidson NE: Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat. 120(3), 581-592 (2010).
130. Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R: Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem. Pharmacol. 70(1), 121-133 (2005). (Pubitemid 40797876)
131. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S: A pilot pharmacokinetic study of oral azacitidine. Leukemia 22(9), 1680-1684 (2008).
132. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
133. Egger G, Aparicio AM, Escobar SG, Jones PA: Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2′- deoxycytidine treatment. Cancer Res. 67(1), 346-353 (2007). (Pubitemid 46142794)
134. Grovdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following mds in complete remission after induction chemotherapy. Br. J. Haematol. 150(3), 293-302 (2010).
135. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56(5), 649-652 (1972).
136. Cunningham TJ, Nemoto T, Rosner D, et al. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271). Cancer Chemother. Rep. 58(5 Pt 1), 677-681 (1974).
137. Quagliana JM, O'Bryan RM, Baker L, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat. Rep. 61(1), 51-54 (1977). (Pubitemid 8100656)
138. Weiss AJ, Metter GE, Nealon TF, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat. Rep. 61(1), 55-58 (1977). (Pubitemid 8100657)
139. Velez-Garcia E, Vogler WR, Bartolucci AA, Arkun SN: Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a Phase II study. Cancer Treat. Rep. 61(9), 1675-1677 (1977). (Pubitemid 8260041)
140. Srinivasan U, Reaman GH, Poplack DG, Glaubiger DL, Levine AS: Phase II study of 5-azacytidine in sarcomas of bone. Am. J. Clin. Oncol. 5(4), 411-415 (1982). (Pubitemid 12064502)
141. Sessa C, ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F: Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group. Eur. J. Cancer 26(2), 137-138 (1990). (Pubitemid 20121864)
142. Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter TA, Renard J: 5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix. Eur. J. Cancer 27(2), 216-217 (1991).
143. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J: Pilot Phase I-II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8(4), 358-368 (1997). (Pubitemid 27204954)
144. Samlowski WE, Leachman SA, Wade M, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J. Clin. Oncol. 23(17), 3897-3905 (2005). (Pubitemid 46218692)
145. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 12(19), 5777-5785 (2006). (Pubitemid 44629609)
146. Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a Phase I trial in refractory solid tumors and lymphomas. Clin. Cancer Res. 15(11), 3881-3888 (2009).
147. A Phase I/II study of azacitidine, docetaxel, and prednisone for metastatic prostate cancer patients previously treated with docetaxel http://clinicaltrials.gov/ct2/show/NCT00503984
148. Low dose decitabine + interferon a-2b in advanced renal cell carcinoma http://clinicaltrials.gov/ct2/show/NCT00561 912?term=NCT00561912&rank=1
149. Azacitidine and interferon a-2b in treating patients with stage III or stage IV melanoma or stage IV kidney cancer that cannot be removed by surgery http://clinicaltrials.gov/ct2/show/NCT00217 542?term=NCT00217542&rank=1
150. A study to evaluate the effectiveness of 5-azacitidine and bevacizumab in advanced renal cell carcinoma (5-AZ) http://clinicaltrials.gov/ct2/show/NCT0093 4440?term=NCT00934440&rank=1